[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636119":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":12,"centralContacts":37,"locations":43,"responsibleParty":85,"collaborators":89,"id":91,"slug":92,"hasResults":93,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":12,"eligibilityCriteria":97,"healthyVolunteers":93,"sex":98,"minAge":99,"maxAge":12,"enrollmentInfo":100,"targetDuration":12,"studyType":103,"phases":104,"briefSummary":106,"conditions":107,"keywords":111,"overallStatus":46,"whyStopped":12,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Texas Tech University Health Sciences Center, El Paso","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"No extended oral antibiotic prophylaxis","NO_INTERVENTION","No additional extended oral antibiotic prophylaxis beyond institutional perioperative protocols.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Extended oral antibiotic prophylaxis","EXPERIMENTAL","Extended oral antibiotic therapy in addition to institutional protocols for perioperative antibiotic therapy",[18,19,20],"Drug: Cefadroxil 500 mg Capsules","Drug: Clindamycin","Drug: Bactrim DS",[22,29,33],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Cefadroxil 500 mg Capsules","Cefadroxil 500 mg, twice a day for 7 days",[14],[28],"Duricef",{"type":23,"name":30,"description":31,"armGroupLabels":32,"otherNames":12},"Clindamycin","Clindamycin 300 mg, three times a day for 7 days",[14],{"type":23,"name":34,"description":35,"armGroupLabels":36,"otherNames":12},"Bactrim DS","Bactrim DS, twice a day for 7 days",[14],[38],{"name":39,"role":40,"phone":41,"phoneExt":12,"email":42},"Taylor M Yong, MD, MS","CONTACT","915-215-5480","tayong@ttuhsc.edu",[44,63,77],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"University of Southern California","RECRUITING","Los Angeles","California","90033","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-118.24368,34.05223,{"lat":56,"lon":55},[59],{"name":60,"role":40,"phone":61,"phoneExt":12,"email":62},"Sarah Blumenthal, MD","800-872-2273","Sarah.Blumenthal@med.usc.edu",{"facility":64,"status":46,"city":65,"state":66,"zip":67,"country":50,"countryCode":51,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"University Medical Center of El Paso","El Paso","Texas","79905",{"type":53,"coordinates":69},[70,71],-106.48693,31.75872,{"lat":71,"lon":70},[74],{"name":75,"role":40,"phone":76,"phoneExt":12,"email":42},"Taylor Yong","8322027406",{"facility":78,"status":46,"city":65,"state":66,"zip":79,"country":50,"countryCode":51,"cosmosGeoPoint":80,"geoPoint":82,"contacts":83},"Texas Tech Health El Paso","79912",{"type":53,"coordinates":81},[70,71],{"lat":71,"lon":70},[84],{"name":39,"role":40,"phone":41,"phoneExt":12,"email":42},{"type":86,"investigatorFullName":87,"investigatorTitle":88,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Taylor M. Yong","Assistant Professor",[90],{"name":45,"class":6},"100636119","phase-4-extended-oral-antibiotic-prophylaxis-in-diabetic-fracture-patients-100636119",false,"NCT07561541","Extended Oral Antibiotic Prophylaxis in Diabetic Fracture Patients","Extended Oral Antibiotic Prophylaxis in Diabetic Patients With Lower Extremity Fracture: A Multicenter Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Low extremity fracture requiring surgical treatment\n* Uncontrolled diabetes (Hemoglobin A1c \\> 7.0 or random glucose \\> 200 mg\u002FdL)\n* Age 18 years or older\n* Able to provide informed consent\n* English or Spanish speaker\n\nExclusion Criteria:\n\n* Known allergy to prescribed antibiotic and pre-determined alternatives\n* Open fractures\n* Current infection requiring antibiotic treatment\n* Immunocompromised status (chemotherapy, immunosuppressant medications)\n* End-stage renal disease that medication dosing cannot be adjusted for\n* Pregnant or breast-feeding\n* Unable to comply with follow-up","ALL","18 Years",{"count":101,"type":102},40,"ESTIMATED","INTERVENTIONAL",[105],"PHASE4","The goal of this clinical trial is to learn if taking an antibiotic pill for 7 days after surgery reduces the risk of wound infection in adults with poorly controlled diabetes who have surgery to fix a broken bone in the leg, ankle, or foot. It will also learn about the safety of the extended antibiotic course. The main questions it aims to answer are:\n\nDoes a 7-day antibiotic course after surgery lower the rate of wound infection within 90 days? What medical problems do participants have when taking the extended antibiotic course?\n\nResearchers will compare a 7-day course of an oral antibiotic (cefadroxil) to standard care (no additional antibiotics after surgery) to see if the extended course reduces infections.\n\nParticipants will:\n\nTake an antibiotic pill or receive standard care for 7 days after surgery Receive a phone call from the study team about 1 week after surgery Visit the clinic at 3 weeks, 6 weeks, and 3 months after surgery for checkups",[108,109,110],"Fracture Lower Leg","Diabetes","Fracture Fixation, Internal",[109,112,14],"Lower extremity fracture","2026-05-06",{"date":115,"type":116},"2026-05-08","ACTUAL",{"date":118,"type":116},"2026-04-01",{"date":120,"type":102},"2027-12-31",{"name":5,"class":6},3]